Tag: glucose-dependent insulinotropic peptide

1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of patients achieving HbA1c targets of less than 7.0%. 2. Compared to placebo, the proportion of adverse events with tirzepatide were mildly elevated. Evidence Rating Level: 1 (Excellent) Study Rundown: In many patients...